In vivo CRISPR gene editing
Intellia Therapeutics is pioneering in vivo CRISPR gene editing — delivering gene editing therapies directly inside the body. Co-founded by Jennifer Doudna, Intellia's lead program uses lipid nanoparticles to deliver CRISPR to the liver.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| NTLA-2001 | ATTR Amyloidosis | Phase 3 | In vivo CRISPR |
| NTLA-2002 | Hereditary Angioedema | Phase 3 | In vivo CRISPR |
| NTLA-3001 | Alpha-1 Antitrypsin Deficiency | Phase 1 | In vivo CRISPR |
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.